BCMA definition

BCMA means B-Cell Maturation Antigen.

AI-Powered Contracts

Draft, Review & Redline at the Speed of AI

BCMA means B-cell maturation antigen.

BCMA means the specific Antigen (or part thereof) coded for by reference to the sequence defined in Schedule 1 under the BCMA-CAR Program; “[***]” means [***] in which one of the [***] intended to [***] on the [***] is capable of binding to [***]; “[***] Option” means Autolus’s rights under Clause 7; “[***] Field” means all uses without restriction except for use in [***];

Examples of BCMA in a sentence

The BCMA will not condone or support a withdrawal of services contrary to the guidance provided by the College of Physicians and Surgeons of British Columbia.
If the Government and the BCMA are unable to agree upon the chair of the conciliation panel either of them may request the Chief Justice of the Supreme Court of British Columbia to make the appointment and the individual so appointed will be the chair of the conciliation panel.
On receipt of the Direct Licence from CRUK, Autolus shall be entitled to deduct an amount equivalent to any sums Autolus pays CRUK under the Direct Licence from any amount Autolus is due to pay UCLB with respect to the GD2 Product, the TRBC1/2 Product (including the [***]) and the BCMA Product.
Functional Ability Forms (FAF) requested by the Employer, will be paid by the Employer in accordance with the BCMA fee guide.
For the purposes of this Clause, “CRUK Rights” shall mean those parts of the licences hereunder to Autolus where (i) CRT is the head licensor to UCLB which includes the GD2 Clinical Study Results and the [***]; or (ii) the CRUK Funders have directly funded the development of the licensed Intellectual Property being certain of the BCMA Program IP.

More Definitions of BCMA

BCMA means the receptor described in International Patent ---- Application [*].

BCMA or the “Administrator” shall mean the British Columbia Medical Association as administrator of the BCMA Health Benefits Trust Fund;

BCMA means an agreement between the Company, Cowen and Chardan, entered into on or about December 7, 2017.

BCMA means British Columbia Medical Association;

BCMA means B-cell maturation antigen. 1.8 “Belamaf” has the meaning set forth in the Recitals hereto. 1.9 “Bioanalytical Testing” has the meaning set forth in Section 9.3. 1.10 “Biomarkers” mean any naturally occurring molecule, gene or characteristic by which a particular pathological or physiological process can be identified and serially monitored during a therapeutic intervention, including blood (including cells, RNA and circulating multiple myeloma cells (CMMCs)), serum (including cytokines and sBCMA), plasma (including cfDNA), tissue and tumors (including FFPE bone marrow aspirate and biopsy Samples). 1.11 “Biomarker Testing” has the meaning set forth in Section 9.2. 1.12 “Business Day” means any day other than (a) a Saturday, Sunday or any public holiday in Boston, Massachusetts or London, England; and (b) a day falling within the time period from and including 24 December up to and including 1 January. 1.13 “cGMP” means the current Good Manufacturing Practices officially published and interpreted by EMA, FDA and other applicable Regulatory Authorities that may be in effect from time to time and are applicable to the Manufacture of the Compounds. These include requirements set forth in FDA’s regulations at 21 CFR Parts 11, 210, 211 and 600, as applicable to the processing, manufacture, handling, receipt, packaging, labelling, release and distribution of products and services subject to this Agreement. 1.14 “Change of Control” of a Party means any of the following, in a single transaction or a series of related transactions: (a) the sale or disposition of all or substantially all of the assets of such Party to a Third Party, (b) the direct or indirect acquisition by a Third Party (other than an employee benefit plan (or related trust) sponsored or maintained by such Party or any of its Affiliates) of beneficial ownership of more than fifty percent (50%) of

BCMA means the specific Antigen (or part thereof) coded for by reference to the sequence defined in Schedule 1 under the BCMA-CAR Program; CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. EXHIBIT 10.1 ***Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(B)(4) and 230.406 “[***]” means [***] in which one of the [***] intended to [***] on the [***] is capable of binding to [***]; “[***] Option” means Autolus’s rights under Clause 7; “[***] Field” means all uses without restriction except for use in [***]; “[***] Licence” has the meaning set out in Clause 2.2.2;

BCMA means the specific Antigen (or part thereof) coded for by reference to the sequence defined in Schedule 1 under the BCMA-CAR Program;